The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News - iShares Biotechnology ETF (NASDAQ:IBB)

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Johnson & Johnson (NYSE:JNJ) got the ball rolling on large-cap biopharma earnings, with mixed results. The positive forward outlook, however, lent support to the stock. Edwards Lifesciences Corporation (NYSE:EW) came under pressure following an earnings miss.

Among other noteworthy developments, the Pfizer (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) alliance and Moderna, Inc. (NASDAQ:MRNA) separately commenced their omicron-specific COVID-19 vaccine studies.

Here are the key catalysts that could impact stocks in the unfolding week:

Clinical Readouts/Presentations

Athersys, Inc. (NASDAQ:ATHX) is scheduled to host a webcast on Wednesday, at 10 a.m. EST, wherein it will make a presentation on its MultiStem clinical programs. The company is due to present an outlook of its ischemic stroke program, including perspectives on the upcoming Phase 2/3 TREASURE data readout. The study is evaluating over 200 stroke patients.

Athersys will also present clinical data from the MultiStem acute respiratory distress syndrome program, including data from both the MUST-ARDS and the ONE-BRIDGE clinical trials. Reflecting on the combined clinical data and supporting information, the company's management will provide its outlook for MultiStem for the treatment of ARDS and its plans for moving the program forward.

Earnings

Tuesday

Catalent, Inc. (NYSE:CTLT) (before the market open)

Wednesday

Thursday

Friday

IPO Quiet Period Expiry

Vigil Neuroscience, Inc. (NASDAQ:VIGL)
CinCor Pharma, Inc. (NASDAQ:CINC)
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Gilead Sciences, Inc. (NASDAQ:GILD) faced a setback after the Food and Drug Administration placed its clinical involving magrolimab on hold. Magrolimab, a anti-CD47 antibody, was acquired as part of the company's $4.9 billion deal to buy of Forty Seven. The antibody treatment is being evaluated with azacytidine in five blood cancer studies, including three Phase 3 studies.

Here are the key catalysts that could impact stocks in the unfolding week:

Clinical Readouts/Presentations

Earnings

Tuesday

Catalent, Inc. (NYSE:CTLT) (before the market open)

Wednesday

Novartis AG (NYSE:NVS) (before the market open)
AbbVie Inc. (NYSE:ABBV) (before the market open)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) (after the close)
Hologic, Inc. (NASDAQ:HOLX) (after the market close)

Thursday

Roche Holding AG (OTC:RHHBY) (before the market open)
Abiomed, Inc. (NASDAQ:ABMD) (before the market open)
Biogen Inc. (NASDAQ:BIIB) (before the market open)
Merck & Co., Inc. (NYSE:MRK) (before the market open)
Eli Lilly and Company (NYSE:LLY) (before the market open)
Cardiovascular Systems, Inc. (NASDAQ:CSII) (after the market close)

Friday

Sanofi (NYSE:SNY) (before the market open)
Bristol-Myers Squibb Company (NYSE:BMY) (before the market open)
IRadimed Corporation (NASDAQ:IRMD) (before the market open)
Meridian Bioscience, Inc. (NASDAQ:VIVO) (before the market open)
Twist Bioscience Corporation (NASDAQ:TWST) (before the market open)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) (before the market open)